Title: Gliosarcomas: Are They Still Dreadful?

Authors: Balu. S, Sridhar. P, Rahul Loni, Vedamanasa I.

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i8.18

Abstract

Introduction: Gliosarcomas are highly malignant tumours of the central nervous system, having the worst prognosis. Gliosarcomas have the same epidemiology and natural history like Glioblastoma whereas the incidence is more among Males compared to females. Gliomas can lead to sarcomatous transformation in the supporting mesenchymal element, affecting the temporal lobe commonly. Gliosarcoma is diagnosed based on gliomatous and malignant mesenchymal differentiation seenon biphasic tissue pattern.

Materials and Methods: 16 patients aged between 32 – 70 years were analyzed. 10 cases were Primary gliosarcoma and 6 cases were secondary gliosarcoma. All patients underwent tumor excision and received adjuvant concurrent chemo radiation therapy followed by adjuvant chemotherapy alone.

Results: In our case series, median survival was 15.6months. Subset analysis showed better median survival in primary gliosarcoma patients.

Conclusion: Maximal safe resection followed by concurrent chemoradiation and adjuvant chemotherapy should be the standard management in primary/secondary gliosarcoma patients.

Keywords: GBM: Glioblastoma, PGS: Primary Gliosarcoma, SGS: Secondary Gliosarcoma, IMRT: Intensity Modulated Radiotherapy .

References

  1. Meis JM, Martz KL, Nelson JS.Mixed glioblastoma multiforme and sarcoma.A clinicopathologic study of 26 radiation therapy oncology group cases. Cancer 1991;67:2342-2349.
  2. Morantz RA, Feigin I, Ransohoff J. Clinical and pathological study of 24 cases of gliosarcoma. J Neurosurg1976;45:398-408.
  3. Stroebe H. Ueber Entstehung und Bau der Gehirnglioma. Beitr Pathol Anat Allg Pathol. 1895;19:405–486.
  4. Galanis E, Buckner JC, Dinapoli RP, et al. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg. 1998;89:425–430.
  5. Sarkar M, Sharma MC, Sudha K, Gaikwad S, Varma A. A clinico-pathological study of 29 cases of gliosarcoma with special reference to two unique variants. Indian J Med Res. 1997;106:229–235.
  6. Parekh HC, O’Donovan DG, Sharma RR, Keogh AJ. Primary cerebral gliosarcoma: report of 17 cases. Br J Neurosurg. 1995;9:171–178.
  7. Sreenan J, Prayson RA. Gliosarcoma: a study of 13 tumors, including p53 and CD34 immunohistochemistry. Arch Pathol Lab Med. 1997;121:129–133.
  8. Biernat W, Aguzzi A, Sure U, Grant JW, Kleihues P, Hegi ME. Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous compo-nents of gliosarcomas suggest a common origin from glial cells. J Neuropathol Exp Neurol. 1995;54:651–656.
  9. Reis RM, Konu-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. Am J Pathol 2000; 156: 425-432.
  10. Ohgaki H, Biernat W, Reis R, Hegi M, Kleihues P. Gliosarcoma. In: Kleihues P, Cavenee WK (eds). Pathology and Genetic of Tumors of the Nervous System, 2nd edn. Lyon: IARC Press, 2000; 42- 44.
  11. Galanis E, Buckner JC, Dinapoli RP, et al. Clinical outcome of gliosarcoma compared with glioblastoma: North Central Cancer Treatment Group results. J Neurosurg 1998;89:425–30.
  12. John A Ozolek, Sydney D Finkelstein and Marta E Couce. Gliosarcoma with epithelial differentiation: immunohistoc-hemical and molecular characterization. A case report and review of the literature. Modern Pathology 2004; 17, 739-745.
  13. Kevin R. Kozak, Anand Mahadevan and John S. Moody Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncology 2009;11, 183-191.
  14. Perry JR, Ang LC, Bilbao JM, Muller PJ. Clinicopathologic features of primary and postirradiationcerebralgliosarcoma. Cancer 1995; 75: 2910–2918
  15. Galanis E, Buckner JC, Dinapoli RP et al. Clinicaloutcome of gliosarcoma compared with glioblastomamultiforme: North Central Cancer Treatment Group results. J Neurosurg 1998; 89: 425–430
  16. Lutterbach J, Guttenberger R, Pagenstecher A. Gliosarcoma: a clinical study. Radiother Oncol 2001; 61:57–64.
  17. Han SJ, Yang I, Tihan T, Prados MD, ParsaAT.Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as aunique oncologic entity. J Neurooncol 2010; 96: 313–320.
  18. Salvati M, Caroli E, Raco A, Giangaspero F, Delfini R, Ferrante L. Gliosarcomas: analysis of 11 cases do twosubtypes exist? J Neurooncol 2005; 74: 59–63.

Corresponding Author

Sridhar. P

Assistant Professor, Department of Radiation Oncology,

Kidwai Cancer Institute, Bangalore-29

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.